Immunogenicity and efficacy of two types of West Nile virus-like particles different in size and maturation as a second-generation vaccine candidate
- PMID: 20678586
- DOI: 10.1016/j.vaccine.2010.07.055
Immunogenicity and efficacy of two types of West Nile virus-like particles different in size and maturation as a second-generation vaccine candidate
Abstract
Virus-like particles (VLPs) of flaviviruses generated from the prM and E genes are a promising vaccine candidate. We have established cell clones continuously releasing VLPs of West Nile virus (WNV) in serum-free conditions. Two types of VLPs were distinguished by sedimenting analyses in sucrose density gradients. Fast sedimenting VLPs (F-VLPs) were large (40-50 nm) and composed of the E and processed mature M proteins, whereas slowly sedimenting VLPs (S-VLPs) were small (20-30 nm) particles consisting of the E and immature prM proteins. F-VLPs induced higher neutralizing antibody and anti-WNV IgG titers than S-VLPs. Furthermore, IgG2a was dominant over IgG1 by immunization with F-VLPs as with whole virion-derived antigens. Mice vaccinated with a low dose (3 ng) of F-VLPs showed higher protective efficacy (83% survivals) against WNV infection than S-VLP-immune mice (17% survivals). These results indicate that F-VLPs more closely resemble the virions and take a better immunogenic form than S-VLPs as WNV vaccine candidates.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Similar articles
-
A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII.Vaccine. 2011 Aug 26;29(37):6352-7. doi: 10.1016/j.vaccine.2011.04.116. Epub 2011 May 17. Vaccine. 2011. PMID: 21596075
-
A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity.J Infect Dis. 2007 Jun 1;195(11):1607-17. doi: 10.1086/517613. Epub 2007 Apr 17. J Infect Dis. 2007. PMID: 17471430
-
Matrix-M™ adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice.Vaccine. 2014 Feb 7;32(7):800-8. doi: 10.1016/j.vaccine.2013.12.030. Epub 2013 Dec 28. Vaccine. 2014. PMID: 24380682
-
Mapping and analysis of West Nile virus-specific monoclonal antibodies: prospects for vaccine development.Expert Rev Vaccines. 2007 Apr;6(2):183-91. doi: 10.1586/14760584.6.2.183. Expert Rev Vaccines. 2007. PMID: 17408368 Review.
-
ChimeriVax-West Nile vaccine.Curr Opin Mol Ther. 2007 Oct;9(5):498-504. Curr Opin Mol Ther. 2007. PMID: 17932814 Review.
Cited by
-
Plant-made vaccines against West Nile virus are potent, safe, and economically feasible.Biotechnol J. 2015 May;10(5):671-80. doi: 10.1002/biot.201400428. Epub 2015 Feb 9. Biotechnol J. 2015. PMID: 25676782 Free PMC article. Review.
-
Epitope resurfacing on dengue virus-like particle vaccine preparation to induce broad neutralizing antibody.Elife. 2018 Oct 18;7:e38970. doi: 10.7554/eLife.38970. Elife. 2018. PMID: 30334522 Free PMC article.
-
Zika virus-like particle vaccine fusion loop mutation increases production yield but fails to protect AG129 mice against Zika virus challenge.PLoS Negl Trop Dis. 2022 Jul 6;16(7):e0010588. doi: 10.1371/journal.pntd.0010588. eCollection 2022 Jul. PLoS Negl Trop Dis. 2022. PMID: 35793354 Free PMC article.
-
An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.J Virol. 2017 Nov 14;91(23):e01181-17. doi: 10.1128/JVI.01181-17. Print 2017 Dec 1. J Virol. 2017. PMID: 28956764 Free PMC article.
-
Different applications of virus-like particles in biology and medicine: Vaccination and delivery systems.Biopolymers. 2016 Mar;105(3):113-32. doi: 10.1002/bip.22759. Biopolymers. 2016. PMID: 26509554 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical